Welcome to our dedicated page for Adagene news (Ticker: ADAG), a resource for investors and traders seeking the latest updates and insights on Adagene stock.
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company focused on antibody-based cancer immunotherapies, and its news flow reflects ongoing clinical, regulatory, scientific, and partnering activity. The company reports that it combines computational biology and artificial intelligence within its Dynamic Precision Library platform, which includes NEObody, SAFEbody, and POWERbody technologies, to design novel antibodies for oncology.
News about Adagene frequently centers on its lead program, ADG126 (muzastotug), a masked, anti-CTLA-4 SAFEbody targeting regulatory T cells in the tumor microenvironment. Recent announcements have covered Phase 1b/2 data in metastatic microsatellite-stable colorectal cancer without liver metastases, initiation of a randomized Phase 2 dose optimization study in combination with pembrolizumab, and the FDA’s Fast Track Designation for muzastotug plus pembrolizumab in a defined MSS metastatic colorectal cancer population. Regulatory updates, such as outcomes from a Type B (End of Phase 1) meeting with the FDA and alignment on Phase 2 and Phase 3 trial designs and endpoints, are also key elements of the company’s news.
Adagene’s press releases additionally highlight strategic collaborations and transactions. Examples include a strategic investment and clinical collaboration with Sanofi to support development of ADG126 and additional SAFEbody discovery programs, an expanded collaboration with Exelixis to develop masked antibody-drug conjugates, a licensing agreement with Third Arc Bio for masked CD3 T cell engagers, and a partnership with ConjugateBio to provide a proprietary antibody for bispecific ADC development. Corporate updates, participation in investor conferences, and leadership appointments in immuno-oncology are also part of the company’s public communications.
Investors and observers following ADAG news can expect coverage of clinical trial progress for ADG126, regulatory milestones, data presentations at scientific meetings, and developments in Adagene’s collaborations that leverage its SAFEbody precision masking technology and Dynamic Precision Library platform.
Adagene Inc. (Nasdaq: ADAG), a clinical-stage biopharmaceutical company, announced that its CEO, Peter Luo, Ph.D., will present at two upcoming conferences: the Jefferies Virtual Healthcare Conference on June 4, 2021, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021. At these events, Adagene will discuss its innovative approaches in antibody-based cancer immunotherapies using its proprietary DPL platform, which includes NEObody, SAFEbody, and POWERbody technologies.
Adagene Inc. (Nasdaq: ADAG) announced positive Phase I clinical trial results for its anti-CD137 antibody, ADG106, showcasing a favorable safety profile and promising efficacy in patients with advanced solid tumors and non-Hodgkin lymphoma. Key findings include a 56% disease control rate and significant tumor shrinkage (over 30%) in 75% of biomarker-positive patients. The company plans to enhance patient stratification using the identified predictive biomarker in upcoming trials. ADG106's innovative design leverages Adagene's proprietary NEObody platform, aiming for future advancements in precision immuno-oncology.
Adagene Inc. has successfully completed its Initial Public Offering, raising approximately US$161 million in gross proceeds. The company reported a 46% increase in net revenue for 2020, totaling US$0.7 million, while research and development expenses surged by 107% to US$33.5 million. The net loss attributable to shareholders increased by 158%, reaching US$42.4 million. Adagene is advancing its NEObody™ and SAFEbody™ programs, initiating clinical trials and establishing partnerships to enhance its pipeline.
Adagene Inc. (Nasdaq: ADAG) announced encouraging results from its ongoing Phase 1 trial of ADG116, a novel anti-CTLA-4 monoclonal antibody for advanced solid tumors. Interim data show ADG116 is well-tolerated, with no dose-limiting toxicities and significant pharmacodynamic signals indicating immune activation. A patient previously resistant to pembrolizumab showed notable immune responses. The trial has progressed to a 0.3 mg/kg dose level, with plans for global expansion and acceptance of a revised protocol by the FDA and China's NMPA. These developments position ADAG for potential market growth.
Adagene Inc. (Nasdaq: ADAG) has initiated its global Phase 1 clinical trial of ADG126, a monoclonal antibody targeting CTLA-4, for advanced solid tumors. This milestone follows the dosing of the first patients and aims to assess the drug's safety and efficacy. The trial will evaluate five dosing levels and has FDA approval for U.S. sites. ADG126 utilizes SAFEbody technology to enhance safety and therapeutic effectiveness by activating antibodies in the tumor microenvironment, addressing the safety concerns of existing CTLA-4 therapies.
Adagene Inc. (Nasdaq: ADAG) has successfully closed its initial public offering (IPO) of 8,457,100 American depositary shares (ADSs) priced at $19.00 each, raising approximately $161 million in gross proceeds. This includes the full exercise of the underwriters’ option for an additional 1,103,100 ADSs. The ADSs began trading on February 9, 2021. The company focuses on developing antibody-based cancer immunotherapies using advanced technologies. Goldman Sachs, Morgan Stanley, and Jefferies acted as joint bookrunners for the offering.
Adagene Inc. (Nasdaq: ADAG) has priced its initial public offering (IPO) at US$19.00 per American depositary share (ADS), raising approximately US$140 million. The IPO consists of 7,354,000 ADSs and will begin trading on February 9, 2021. The offering will close on February 11, 2021, pending customary conditions. Underwriters have a 30-day option to purchase an additional 1,103,100 ADSs for over-allotments. Goldman Sachs, Morgan Stanley, and Jefferies are the lead underwriters of this offering.